Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Nkarta's NKX-19?
NKX-19 is a gene-modified cell therapy commercialized by Nkarta, with a leading Phase I program in B-Cell Chronic Lymphocytic Leukemia;Relapsed...
Data Insights
Risk adjusted net present value: What is the current valuation of Nkarta's NKX-19?
NKX-19 is a gene-modified cell therapy commercialized by Nkarta, with a leading Phase I program in B-Cell Acute Lymphocytic Leukemia...